"...We have aggressive plans to grow not only in India but globally. We see huge opportunities for us to expand our manufacturing in Punjab and our facilities coming back in compliance when we are able to commercially exploit products for which company has made investments in the past," Sun Pharma MD Dilip Shanghvi said here while addressing Investors Summit today.
"It is a great blessing for us that post our acquisition of Ranbaxy, we have made significant investments in manufacturing in Punjab. Our prime focus is to bring facilities of Ranbaxy back to compliance so that these investments will start producing returns."